The Relationship Among Ki-67, ERBB2, GATA3, STAG2, P53, and YAP1 in Pancreatic Ductal Adenocarcinoma

Victoria Hodges; Christie Fumbah; Junaith Mohamed; Sheila Criswell

doi:doi:10.11648/j.crj.20221003.12

| Peer-Reviewed

The Relationship Among Ki-67, ERBB2, GATA3, STAG2, P53, and YAP1 in Pancreatic Ductal Adenocarcinoma

Victoria Hodges, Christie Fumbah, Junaith Mohamed, Sheila Criswell

Published in Cancer Research Journal (Volume 10, Issue 3)

Received: 15 June 2022 Accepted: 29 June 2022 Published: 12 July 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal forms of cancer with a 5-year survival of only 7% for both men and women. Despite substantial progress made in successfully personalizing treatment for other tumors such as breast, prostate, and lung, treatment for PDA remains elusive due, in part, to its unique growth pattern and lack of surveillance tools to detect early lesions. Because most PDA lesions have metastasized at the time of diagnosis and exhibit a heterogeneously infiltrative growth pattern by interdigitating malignant cells among various normal tissue components, decisive, targeted therapies are needed to remove tumor cells while leaving the surrounding benign tissues undamaged. In an effort to identify biomarkers, immunohistochemistry assays were employed to determine the expression of Ki-67, KLK7, YAP1, CK 5, CK 20, CEA, GATA3, XAF1, STAG2, CK 18, ERBB2, and P53 in 42 formalin-fixed, paraffin-embedded PDA samples. Although no statistically significant correlation was associated with tumor aggressiveness as determined by Ki-67 positivity, several pairs of markers demonstrated positive correlations with each other and included ERBB2/STAG2, ERBB/YAP1, ERBB/GATA3, ERBB/P53, GATA3/STAG2, and GATA3/YAP1. Characterization of individual tumors with respect to over- or under-expression of specific proteins may offer dual therapy targets in PDA to potentially improve patient outcomes.

Published in	Cancer Research Journal (Volume 10, Issue 3)
DOI	10.11648/j.crj.20221003.12
Page(s)	61-69
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Cancer, Pancreas, Therapy

References

[1]	Siegel R, Miller K, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65 (1): 5-29. doi: 10.3322/caac.21254.
[2]	Chen W, He D, Tang R, Ren F, Chen G. Ki-67 is a valuable prognostic factor in gliomas: evidence from a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2015; 16 (2): 411-20. doi: 10.7314/apjcp.2015.16.2.411.
[3]	Piri R, Ghaffari A, Azami-Aghdash S, Ali-Akbar YP, Saleh P, Naghavi-Behzad M. Ki-67/MIB-1 as a Prognostic Marker in Cervical Cancer - a Systematic Review with Meta-Analysis. Asian Pac J Cancer Prev. 2015; 16 (16): 6997-7002. doi: 10.7314/apjcp.2015.16.16.6997.
[4]	Pezzilli R, Partelli S, Cannizzaro R, Pagano N, Crippa S, Pagnanelli M, Falconi M. Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs): A systematic review. Adv Med Sci. 2016; 61 (1): 147-53. doi: 10.1016/j.advms.2015.10.001.
[5]	Berlin A, Castro-Mesta JF, Rodriguez-Romo L, Hernandez-Barajas D, González-Guerrero JF, Rodríguez-Fernández IA, González-Conchas G, Verdines-Perez A, Vera-Badillo FE. Prognostic role of Ki-67 score in localized prostate cancer: A systematic review and meta-analysis. Urol Oncol. 2017; 35 (8): 499-506. doi: 10.1016/j.urolonc.2017.05.004.
[6]	Menon S, Guruvayoorappan C, Sakthivel K, Rasmi R. Ki-67 protein as a tumour proliferation marker. Clin Chim Acta. 2019; 491: 39-45. doi: 10.1016/j.cca.2019.01.011.
[7]	Davey M, Hynes S, Kerin M, Miller N, Lowery A. Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. Cancers (Basel). 2021; 13 (17): 4455. doi: 10.3390/cancers13174455.
[8]	Zhang Y, Yang J, Li H, Wu Y, Zhang H, Chen W. Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis. Int J Clin Exp Med. 2015; 8 (7): 11683-91.
[9]	Tang Q, Su Z, Gu W, Rustgi A. Mutant p53 on the Path to Metastasis. Trends Cancer. 2020; 6 (1): 62-73. doi: 10.1016/j.trecan.2019.11.004.
[10]	Blagih J, Buck M, Vousden K. p53, cancer and the immune response. J Cell Sci. 2020; 133 (5): jcs237453. doi: 10.1242/jcs.237453. PMID: 32144194.
[11]	Plenchette S, Cheung H, Fong W, LaCasse E, Korneluk R. The role of XAF1 in cancer. Curr Opin Investig Drugs. 2007; 8 (6): 469-76.
[12]	Kyriakopoulou L, Yousef G, Scorilas A, Katsaros D, Massobrio M, Fracchioli S, Diamandis E. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clin Biochem. 2003; 36 (2): 135-43. doi: 10.1016/s0009-9120 (02)00446-0.
[13]	Walker F, Nicole P, Jallane A, Soosaipillai A, Mosbach V, Oikonomopoulou K, Diamandis EP, Magdolen V, Darmoul D. Kallikrein-related peptidase 7 (KLK7) is a proliferative factor that is aberrantly expressed in human colon cancer. Biol Chem. 2014; 395 (9): 1075-86. doi: 10.1515/hsz-2014-0142.
[14]	Khazaeli Najafabadi M, Mirzaeian E, Memar Montazerin S, Tavangar A, Tabary M, Tavangar S. Role of GATA3 in tumor diagnosis: A review. Pathol Res Pract. 2021; 226: 153611. doi: 10.1016/j.prp.2021.153611.
[15]	Szulzewsky F, Holland E, Vasioukhin V. YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance. Dev Biol. 2021; 475: 205-221. doi: 10.1016/j.ydbio.2020.12.018.
[16]	De Koninck M, Lapi E, Badía-Careaga C, Cossío I, Giménez-Llorente D, Rodríguez-Corsino M, Andrada E, Hidalgo A, Manzanares M, Real FX, Losada A. Essential Roles of Cohesin STAG2 in Mouse Embryonic Development and Adult Tissue Homeostasis. Cell Rep. 2020; 32 (6): 108014. doi: 10.1016/j.celrep.2020.108014.
[17]	Koeppen H, Wright B, Burt A, Quirke P, McNicol A, Dybdal N, Sliwkowski M, Jillan K. Overexpression of HER2/neu in solid tumors: an immunohistochemical survey. Histopathology. 2001; 38: 96-104.
[18]	Madani S, Sadeghi E, Rezaee A, Sadeghi M, Khazaee S, Amirifard N, Payandeh M. Survey of HER2-neu expression in colonic adenocarcinoma in the west of Iran. Asian Pacific Journal of Cancer Prevention. 2015; 16 (17): 7671-7674.
[19]	Subramanian J, Katta A, Masood A, Vudem D, Kancha R. Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers. Oncologist. 2019; 24 (12): e1303-e1314. doi: 10.1634/theoncologist.2018-0845.
[20]	Moll R, Franke W, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982; 31 (1): 11-24. doi: 10.1016/0092-8674 (82)90400-7.
[21]	DeJarnatt V & Criswell S. Glyoxal: a proposed substitute for formalin in H&E and special stains, Journal of Histotechnology, 2021; 44: 1, 37-45. DOI: 10.1080/01478885.2020.1830664.
[22]	Mills. S, Klimstra D, Hruban R, Pitman M. Histology for Pathologists. Third Edition. Lippincott Williams and Wilkins; 2007. Chapter 30, 723-755.
[23]	Seymour AB, Hruban RH, Redston M, Caldas C, Powell SM, Kinzler KW, Yeo CJ, Kern SE. Allelotype of pancreatic adenocarcinoma. Cancer Res. 1994 May 15; 54 (10): 2761-4. PMID: 8168108.
[24]	Jeong S, Lee D, Lee J, Lee J, Kwon K, Kim P, Kim H, Shin Y, Kim Y, Kim Y. Expression of Ki-67, p53, and K-ras in chronic pancreatitis and pancreatic ductal adenocarcinoma. World Journal of Gastroenterology. 2005; 11 (43): 6765-6769.
[25]	Klein W, Hruban R, Klein-Szanto A, Wilentz R. Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. Modern Pathology. 2002; 15 (4): 441-447.
[26]	Karamitopoulou E, Xlobec I, Tornillo L, Carafa V, Schaffner T, Brunner T, Borner M, Diamantis I, Zimmermann A, Terracciano L. Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intrepithelial neoplasia (PanIN). Pathology. 2010; 42 (3): 229-234.
[27]	Kim H, Park C, Lee J, Kim J, Cho C, Kim H. Ki-67 and p53 expression as a predictive marker for early postoperative recurrence in pancreatic head cancer. Annals of Surgical Treatment and Research. 2015; 88 (4): 200-207.
[28]	Temraz S, Shamseddine A, Mikherji D, Charafeddine M, Tfayli A, Assi H, Hammoud M, Makki I, Nassif S. Ki67 and p53 in relation to disease progression in metastatic pancreatic cancer: a single institution analysis. 2019; 25: 1059-1066.
[29]	Stanton K, Sidner R, Miller G, Cumming O, Schmidt M, Howard T, Wiebke E. Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas. American Journal of Surgery 2003; 186: 486-492.
[30]	Menz, A., Weitbrecht, T., Gorbokon, N. et al. Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors. Mol Med. 2021; 27: 16. https://doi.org/10.1186/s10020-021-00274-7
[31]	Yamanaka Y, Friess H, Kobrin M, Buechler M, Kunz J, Beger H, Korc M. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Human Pathology. 1993; 24 (10): 1127-1134.
[32]	Lei S, Appert H, Nakata B, Domenico D, Kim K, Howard J. Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. International Journal of Pancreatology. 1995; 17 (1): 15-21.
[33]	Standop J, Schneider M, Ulrich A, Mathiak G, Brand R, Buechler M, Pour P. ErbB2 oncogene antibodies differentiate between the normal and diseased pancreas, and between chronic pancreatitis and pancreatic cancer. Oncology Reports. 2004; 12: 1309-1315.
[34]	Glaser A, Fantini D, Shilatifard A, Schaeffer E, Meeks J. The evolving genomic landscape of urothelial carcinoma. Nature Reviews Urology. 2017; 14: 215-229.
[35]	Chen X, Xuehua L, Pang G, Deng J, Xie Q, Zhang Z. Significance of KDM6A mutation in bladder cancer immune escape. BMC Cancer. 2021; 21: 635.
[36]	Huang J, Nagatomo I, Suzuki E, Mizuno T, Kumagai T, Berezov A, Zhang H, Karlan B, Greene M, Wang Q. YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene. 2013; 32 (17): 2220-2229. doi: 10.1038/onc.2012.231.
[37]	Murakami S, Shahbazian D. Surana R, Zhang W, Chen H, Graham G, White S, Weiner L, Yi C. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Oncogene. 2017; 36 (9): 1232-1244.
[38]	Jaramillo-Rodriguez Y, Cerda-Flores R, Ruiz-Ramos R, Lopez-Marquez F, Calderon-Garciduenas A. YAP expression in normal and neoplastic breast tissue: an immunohistochemical study. Archives of Medical Research. 2014; 45: 223-228.
[39]	Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, Gupta S, Vietsch E, Laughlin S, Wadhwa M, Chetram M, Joshi M, Wang F, Kallakury B, Toretsky J, Wellstein A, Yi C. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Science Signaling. 2008; 7 (324): ra42. Doi: 10.1126/scisignal.20055049.
[40]	Morvaridi S, Dhall D, Greene M, Pandol S, Qang Q. Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and chronic pancreatitis. Scientific Reports. 2015; 5: 16759. Doi: 10.1038/srep16759.
[41]	Gonzalez R, Wang J, Kraus T, Sullivan H, Adams A, Cohen C. GATA-3 expression in male and female breast cancers: comparison of clinicopathologic parameters and prognostic relevance. Human Pathology. 2013; 44: 1065-1070.
[42]	Yildirim E, Bektas S, Gundogar O, Findik D, Alcicek S, Orhun E, Yildiz M. The relationship of GATA3 and Ki-67 with histopathological prognostic parameters, locoregional recurrence and disease-free survival in invasive ductal carcinoma of the breast. Anticancer Research. 2020; 40: 5649-5657.
[43]	Gulbinas A, Berberat P, Dambrauskas Z, Giese T, Giese N, Autschbach F, Kleeff J, Meuer S, Buechler M, Friess H. Aberrant Gata-3 expression in human pancreatic cancer. Journal of Histochemistry and Cytochemistry. 2006; 54 (2): 161-169.
[44]	Agostini-Vulaj D, Bratton L, Dunne R, Cates J, Zhou Z, Findeis-Hosey J, Yang Q, Ramesh M, Gonzalez R. Incidence and signivicance of GATA3 positivity in pancreatic ductal adenocarcinoma and cholangiocarcinoma. Applied Immunohistochemistry and Molecular Morphology. 2002; 28 (6): 460-463.
[45]	Evers L, Perez-Mancera P, Lenkeiwicz E, Tang N, Aust D, Knoesel T, Ruemmele P, Holley T, Kassmer M, Aziz M, Ramanathan R, Von Hoff D, Yin H, Pilarsky C, Barrett M. STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma. Genome Medicine. 2014: 6: 9.
[46]	Gyoerffy R, Pongor L, Bottai G, Li X, Budczies J, Szabo A, Hatzis C, Pusztai L, Santarpia L. An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes. British Journal of Cancer. 2018; 118: 1107-1114.
[47]	Arain S, Arafah M, Raddaoui E, Tulba A, Alkhawaja F, Shedoukby A. Immunohistochemistry of mammary Paget’s disease. Saudi Medical Journal. 2020; 41 (3): 232-237.
[48]	DiGiuseppe J, Hruban R, Goodman S, Polak M, van den Berg F, Allison D, Cameron J, Offerhaus G. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol. 1994; 101 (6): 684-8. doi: 10.1093/ajcp/101.6.684.
[49]	Dong M, Nio Y, Sato Y, Tamura K, Song M, Tian Y, Dong Y. Comparative study of p53 expression in primary invasive ductal carcinoma of the pancreas between Chinese and Japanese. Pancreas. 1998; 17 (3): 229-237.
[50]	Sun T, Hutchinson L, Tomaszewicz K, Caporelli M, Meng X, McCauley K, Fischer A, Cosar E, Cornejo K. Diagnostic value of a comprehensive, urothelial carcinoma-specific next-generation sequencing panel in urine cytology and bladder tumor specimens. Cancer Cytopathology. 2021. Doi: 10.1002/cncy.22410.

Cite This Article

Plain Text BibTeX RIS

APA Style

Victoria Hodges, Christie Fumbah, Junaith Mohamed, Sheila Criswell. (2022). The Relationship Among Ki-67, ERBB2, GATA3, STAG2, P53, and YAP1 in Pancreatic Ductal Adenocarcinoma. Cancer Research Journal, 10(3), 61-69. https://doi.org/10.11648/j.crj.20221003.12

Copy | Download

ACS Style

Victoria Hodges; Christie Fumbah; Junaith Mohamed; Sheila Criswell. The Relationship Among Ki-67, ERBB2, GATA3, STAG2, P53, and YAP1 in Pancreatic Ductal Adenocarcinoma. Cancer Res. J. 2022, 10(3), 61-69. doi: 10.11648/j.crj.20221003.12

Copy | Download

AMA Style

Victoria Hodges, Christie Fumbah, Junaith Mohamed, Sheila Criswell. The Relationship Among Ki-67, ERBB2, GATA3, STAG2, P53, and YAP1 in Pancreatic Ductal Adenocarcinoma. Cancer Res J. 2022;10(3):61-69. doi: 10.11648/j.crj.20221003.12

Copy | Download

@article{10.11648/j.crj.20221003.12,
  author = {Victoria Hodges and Christie Fumbah and Junaith Mohamed and Sheila Criswell},
  title = {The Relationship Among Ki-67, ERBB2, GATA3, STAG2, P53, and YAP1 in Pancreatic Ductal Adenocarcinoma},
  journal = {Cancer Research Journal},
  volume = {10},
  number = {3},
  pages = {61-69},
  doi = {10.11648/j.crj.20221003.12},
  url = {https://doi.org/10.11648/j.crj.20221003.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20221003.12},
  abstract = {Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal forms of cancer with a 5-year survival of only 7% for both men and women. Despite substantial progress made in successfully personalizing treatment for other tumors such as breast, prostate, and lung, treatment for PDA remains elusive due, in part, to its unique growth pattern and lack of surveillance tools to detect early lesions. Because most PDA lesions have metastasized at the time of diagnosis and exhibit a heterogeneously infiltrative growth pattern by interdigitating malignant cells among various normal tissue components, decisive, targeted therapies are needed to remove tumor cells while leaving the surrounding benign tissues undamaged. In an effort to identify biomarkers, immunohistochemistry assays were employed to determine the expression of Ki-67, KLK7, YAP1, CK 5, CK 20, CEA, GATA3, XAF1, STAG2, CK 18, ERBB2, and P53 in 42 formalin-fixed, paraffin-embedded PDA samples. Although no statistically significant correlation was associated with tumor aggressiveness as determined by Ki-67 positivity, several pairs of markers demonstrated positive correlations with each other and included ERBB2/STAG2, ERBB/YAP1, ERBB/GATA3, ERBB/P53, GATA3/STAG2, and GATA3/YAP1. Characterization of individual tumors with respect to over- or under-expression of specific proteins may offer dual therapy targets in PDA to potentially improve patient outcomes.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - The Relationship Among Ki-67, ERBB2, GATA3, STAG2, P53, and YAP1 in Pancreatic Ductal Adenocarcinoma
AU  - Victoria Hodges
AU  - Christie Fumbah
AU  - Junaith Mohamed
AU  - Sheila Criswell
Y1  - 2022/07/12
PY  - 2022
N1  - https://doi.org/10.11648/j.crj.20221003.12
DO  - 10.11648/j.crj.20221003.12
T2  - Cancer Research Journal
JF  - Cancer Research Journal
JO  - Cancer Research Journal
SP  - 61
EP  - 69
PB  - Science Publishing Group
SN  - 2330-8214
UR  - https://doi.org/10.11648/j.crj.20221003.12
AB  - Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal forms of cancer with a 5-year survival of only 7% for both men and women. Despite substantial progress made in successfully personalizing treatment for other tumors such as breast, prostate, and lung, treatment for PDA remains elusive due, in part, to its unique growth pattern and lack of surveillance tools to detect early lesions. Because most PDA lesions have metastasized at the time of diagnosis and exhibit a heterogeneously infiltrative growth pattern by interdigitating malignant cells among various normal tissue components, decisive, targeted therapies are needed to remove tumor cells while leaving the surrounding benign tissues undamaged. In an effort to identify biomarkers, immunohistochemistry assays were employed to determine the expression of Ki-67, KLK7, YAP1, CK 5, CK 20, CEA, GATA3, XAF1, STAG2, CK 18, ERBB2, and P53 in 42 formalin-fixed, paraffin-embedded PDA samples. Although no statistically significant correlation was associated with tumor aggressiveness as determined by Ki-67 positivity, several pairs of markers demonstrated positive correlations with each other and included ERBB2/STAG2, ERBB/YAP1, ERBB/GATA3, ERBB/P53, GATA3/STAG2, and GATA3/YAP1. Characterization of individual tumors with respect to over- or under-expression of specific proteins may offer dual therapy targets in PDA to potentially improve patient outcomes.
VL  - 10
IS  - 3
ER  -

Copy | Download

Author Information

Victoria Hodges

Department of Pathology, Methodist University Hospital, Memphis, USA
Christie Fumbah

Department of Diagnostic and Health Sciences, University of Tennessee Health Science Center, Memphis, USA
Junaith Mohamed

Department of Diagnostic and Health Sciences, University of Tennessee Health Science Center, Memphis, USA
Sheila Criswell

Department of Diagnostic and Health Sciences, University of Tennessee Health Science Center, Memphis, USA

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Victoria Hodges, Christie Fumbah, Junaith Mohamed, Sheila Criswell. (2022). The Relationship Among Ki-67, ERBB2, GATA3, STAG2, P53, and YAP1 in Pancreatic Ductal Adenocarcinoma. Cancer Research Journal, 10(3), 61-69. https://doi.org/10.11648/j.crj.20221003.12

Copy | Download

ACS Style

Victoria Hodges; Christie Fumbah; Junaith Mohamed; Sheila Criswell. The Relationship Among Ki-67, ERBB2, GATA3, STAG2, P53, and YAP1 in Pancreatic Ductal Adenocarcinoma. Cancer Res. J. 2022, 10(3), 61-69. doi: 10.11648/j.crj.20221003.12

Copy | Download

AMA Style

Victoria Hodges, Christie Fumbah, Junaith Mohamed, Sheila Criswell. The Relationship Among Ki-67, ERBB2, GATA3, STAG2, P53, and YAP1 in Pancreatic Ductal Adenocarcinoma. Cancer Res J. 2022;10(3):61-69. doi: 10.11648/j.crj.20221003.12

Copy | Download

@article{10.11648/j.crj.20221003.12,
  author = {Victoria Hodges and Christie Fumbah and Junaith Mohamed and Sheila Criswell},
  title = {The Relationship Among Ki-67, ERBB2, GATA3, STAG2, P53, and YAP1 in Pancreatic Ductal Adenocarcinoma},
  journal = {Cancer Research Journal},
  volume = {10},
  number = {3},
  pages = {61-69},
  doi = {10.11648/j.crj.20221003.12},
  url = {https://doi.org/10.11648/j.crj.20221003.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20221003.12},
  abstract = {Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal forms of cancer with a 5-year survival of only 7% for both men and women. Despite substantial progress made in successfully personalizing treatment for other tumors such as breast, prostate, and lung, treatment for PDA remains elusive due, in part, to its unique growth pattern and lack of surveillance tools to detect early lesions. Because most PDA lesions have metastasized at the time of diagnosis and exhibit a heterogeneously infiltrative growth pattern by interdigitating malignant cells among various normal tissue components, decisive, targeted therapies are needed to remove tumor cells while leaving the surrounding benign tissues undamaged. In an effort to identify biomarkers, immunohistochemistry assays were employed to determine the expression of Ki-67, KLK7, YAP1, CK 5, CK 20, CEA, GATA3, XAF1, STAG2, CK 18, ERBB2, and P53 in 42 formalin-fixed, paraffin-embedded PDA samples. Although no statistically significant correlation was associated with tumor aggressiveness as determined by Ki-67 positivity, several pairs of markers demonstrated positive correlations with each other and included ERBB2/STAG2, ERBB/YAP1, ERBB/GATA3, ERBB/P53, GATA3/STAG2, and GATA3/YAP1. Characterization of individual tumors with respect to over- or under-expression of specific proteins may offer dual therapy targets in PDA to potentially improve patient outcomes.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - The Relationship Among Ki-67, ERBB2, GATA3, STAG2, P53, and YAP1 in Pancreatic Ductal Adenocarcinoma
AU  - Victoria Hodges
AU  - Christie Fumbah
AU  - Junaith Mohamed
AU  - Sheila Criswell
Y1  - 2022/07/12
PY  - 2022
N1  - https://doi.org/10.11648/j.crj.20221003.12
DO  - 10.11648/j.crj.20221003.12
T2  - Cancer Research Journal
JF  - Cancer Research Journal
JO  - Cancer Research Journal
SP  - 61
EP  - 69
PB  - Science Publishing Group
SN  - 2330-8214
UR  - https://doi.org/10.11648/j.crj.20221003.12
AB  - Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal forms of cancer with a 5-year survival of only 7% for both men and women. Despite substantial progress made in successfully personalizing treatment for other tumors such as breast, prostate, and lung, treatment for PDA remains elusive due, in part, to its unique growth pattern and lack of surveillance tools to detect early lesions. Because most PDA lesions have metastasized at the time of diagnosis and exhibit a heterogeneously infiltrative growth pattern by interdigitating malignant cells among various normal tissue components, decisive, targeted therapies are needed to remove tumor cells while leaving the surrounding benign tissues undamaged. In an effort to identify biomarkers, immunohistochemistry assays were employed to determine the expression of Ki-67, KLK7, YAP1, CK 5, CK 20, CEA, GATA3, XAF1, STAG2, CK 18, ERBB2, and P53 in 42 formalin-fixed, paraffin-embedded PDA samples. Although no statistically significant correlation was associated with tumor aggressiveness as determined by Ki-67 positivity, several pairs of markers demonstrated positive correlations with each other and included ERBB2/STAG2, ERBB/YAP1, ERBB/GATA3, ERBB/P53, GATA3/STAG2, and GATA3/YAP1. Characterization of individual tumors with respect to over- or under-expression of specific proteins may offer dual therapy targets in PDA to potentially improve patient outcomes.
VL  - 10
IS  - 3
ER  -

Copy | Download